SAN DIEGO, Oct. 27, 2022 (GLOBE NEWSWIRE) — Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical firm centered on the event of novel oncology therapies, at present introduced that it’s going to report third quarter 2022 monetary outcomes after the U.S. monetary markets shut on Thursday, November 3, 2022. Oncternal’s administration will host a webcast at 2:00 p.m. PT (5:00 p.m. ET) to present a complete business replace and focus on the Company’s monetary outcomes.
The reside webcast of the decision shall be out there on-line at investor.oncternal.com and the decision shall be archived there for at the very least 30 days.
About Oncternal Therapeutics
Oncternal Therapeutics is a clinical-stage biopharmaceutical firm centered on the event of novel oncology therapies for the remedy of sufferers with cancers which have important unmet medical want. Oncternal pursues drug improvement concentrating on promising, but untapped organic pathways implicated in most cancers technology or development, specializing in hematological malignancies and prostate most cancers. The lead scientific program is zilovertamab, an investigational monoclonal antibody designed to inhibit the perform of Receptor Tyrosine Kinase-Like Orphan Receptor 1 (ROR1). ZILO-301, a worldwide Phase 3 Study to consider zilovertamab together with ibrutinib for the remedy of sufferers with relapsed/refractory mantle cell lymphoma (MCL) has been initiated (NCT05431179). Zilovertamab continues to be evaluated in an ongoing Phase 1/2 research together with ibrutinib for the remedy of sufferers with MCL and continual lymphocytic leukemia (CLL), and this trial was not too long ago amended to embody sufferers with marginal zone lymphoma (MZL). Zilovertamab can also be being evaluated in two investigator-initiated research, together with a Phase 2 scientific trial of zilovertamab together with venetoclax, a Bcl-2 inhibitor, in sufferers with relapsed/refractory CLL, and in a Phase 1b research of zilovertamab together with docetaxel in sufferers with metastatic castration-resistant prostate most cancers (mCRPC). Oncternal can also be transferring into the clinic with ONCT-808, an autologous chimeric antigen receptor T (CAR T) cell remedy that targets ROR1, with an energetic U.S. IND as of the top of September 2022 for the remedy of sufferers with relapsed or refractory aggressive B cell lymphoma, together with sufferers who’ve failed earlier CD19 CAR T remedy. The preclinical pipeline additionally contains ONCT-534, a dual-action androgen receptor inhibitor (DAARI) that’s present process ultimate IND-enabling research, as a possible remedy for castration resistant prostate most cancers, together with these with unmet medical want due to resistance to authorized, customary of care androgen receptor inhibitors. More data is out there at https://oncternal.com/.
Contact Information:
Investors
Richard Vincent
858-434-1113
[email protected]
Media
Corey Davis, Ph.D.
LifeSci Advisors
212-915-2577
[email protected]
